To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes during prophylaxis treatment, including neoantigenicity.
An Open-label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) with Severe Hemophilia A.
Eligibility & Criteria
-Ages Eligible for Study: 12 Years and above-Genders Eligible for Study: BothInclusion Criteria: * Severe hemophilia A (FVIII:C less than or equal to 2% at local laboratory) * Previously treated patients with greater than or equal to 250 exposure days to any Factor VIII product * Age greater than or equal to 12 years * History of prophylaxis dosing at least twice per week on any Factor VIII product for at least 3 consecutive months within the 2 years prior to study enrollment unless the patient completed the previous pharmacokinetic study * Adequate laboratory resultsExclusion Criteria: * Presence of any bleeding disorder in addition to hemophilia A * Concomitant therapy with immunosuppressive drugs * Current or historical Factor VIII inhibitor * Treatment with any investigational drug or device within the past 30 days
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.